Cite
Mitochondrial-Targeted Triphenylphosphonium–Hydroxycamptothecin Conjugate and Its Nano-Formulations for Breast Cancer Therapy: In Vitro and In Vivo Investigation.
MLA
Zhang, Kunfeng, et al. “Mitochondrial-Targeted Triphenylphosphonium–Hydroxycamptothecin Conjugate and Its Nano-Formulations for Breast Cancer Therapy: In Vitro and In Vivo Investigation.” Pharmaceutics, vol. 15, no. 2, Feb. 2023, p. 388. EBSCOhost, https://doi.org/10.3390/pharmaceutics15020388.
APA
Zhang, K., Fu, J., Liu, X., Guo, Y., Han, M., Liu, M., & Wang, X. (2023). Mitochondrial-Targeted Triphenylphosphonium–Hydroxycamptothecin Conjugate and Its Nano-Formulations for Breast Cancer Therapy: In Vitro and In Vivo Investigation. Pharmaceutics, 15(2), 388. https://doi.org/10.3390/pharmaceutics15020388
Chicago
Zhang, Kunfeng, Jingxin Fu, Xiaorui Liu, Yifei Guo, Meihua Han, Meifeng Liu, and Xiangtao Wang. 2023. “Mitochondrial-Targeted Triphenylphosphonium–Hydroxycamptothecin Conjugate and Its Nano-Formulations for Breast Cancer Therapy: In Vitro and In Vivo Investigation.” Pharmaceutics 15 (2): 388. doi:10.3390/pharmaceutics15020388.